It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab.
His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria patients previously inadequately controlled with omalizumab; analysis of the Phase 2 program’ was presented at the EADV Virtual Congress, 29-31 October 2020.
- What are the limitations of the current standard of care for chronic spontaneous urticaria? (0:16)
- What is the rationale for the use of ocrelizumab in chronic spontaneous urticaria patients previously inadequately controlled with H1-antihistamines? (0:40)
- Could give us a brief overview of the 2019 Phase II study and its findings? (1:26)
- What have we learned from your recent analyses of this study’s data in terms of possible predictors of response to ligelizumab? (2:18)
- What are the implications of these findings and what further study is needed? (3:06)
Disclosures: Martin Metz was an investigator of this phase II study and has acted as a speaker/ consultant for Novartis.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of EADV Virtual Congress 2020
Share this Video
Related Videos In Dermatological Conditions
Christian Vestergaard, EADV 2021: Biologics for Paediatric Skin Diseases
It was a pleasure to meet Dr Christian Vestergaard (Aarhus University Hospital, Aarhus, Denmark) to discuss the use of biologics in the treatment of paediatric skin diseases. His presentation entitled ‘The use of biological drugs for skin diseases in children’ was presented at the EADV 30th Congress, 29 Sep – 2 Oct 2021. Questions What […]
Rosalie Luiten, EADV 2021: The Role of Resident Memory T-cells in Vitiligo and Tumour Immunity
touchIMMUNOLOGY were delighted to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the role of resident memory T cells in autoimmune vitiligo and tumour immunity, and how they could be used as a therapeutic target. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the […]
Rosalie Luiten, EADV 2021: The Link between Vitiligo and Melanoma
It was a pleasure to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the immunological link between vitiligo and melanoma. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Questions How are vitiligo and melanoma linked? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!